Anti-BRCA2; BRCA2

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 13; NC_000013.10 (32889617..32973809). Location: 13q12.3

Monoclonal

IgG1 kappa

Mouse

This antibody recognizes human BRCA2, a 390 kD nuclear protein. BRCA2 has been associated with predisposition of women to early-onset breast and ovarian cancers. BRCA2 appears to be involved in DNA recombination and double strand break repair.

Purified
100 ug Protein G-purified antibody in PBS,pH 7.4

1.0 mg/ml (lot specific)

Store at 2-8°C for short term.

This antibody is stable at least one year at -70°C for long term. Avoid multiple freeze/thaw cycles.

Small volumes of anti-BRCA2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Cancer Research Products

Immunoblot

Immunoblotting: use at 1-5 ug/ml.
Positive control: Molt 4 cells.

breast cancer 2, early onset

breast cancer type 2 susceptibility protein; OTTHUMP00000018803; fanconi anemia group D1 protein; breast cancer 2 tumor suppressor; BRCA1/BRCA2-containing complex, subunit 2; breast cancer susceptibility protein BRCA2; breast and ovarian cancer susceptibility gene, early onset

Breast cancer type 2 susceptibility protein

FACD; FANCD1??[Similar Products]

BRCA2_HUMAN

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq]

BRCA2: involved in double-strand break repair and/or homologous recombination. May participate in S phase checkpoint activation. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with PALB2, enables the recombinational repair and checkpoint functions. Interacts with WDR16. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer and may underlie susceptibility to uveal melanoma.

Protein type: Nuclear receptor co-regulator; DNA repair, damage; Tumor suppressor

Chromosomal Location of Human Ortholog: 13q12.3

Cellular Component: nucleoplasm; centrosome; protein complex; cytoplasm; BRCA2-MAGE-D1 complex; nucleus; secretory granule

Molecular Function: protein binding; H4 histone acetyltransferase activity; gamma-tubulin binding; histone acetyltransferase activity; protease binding; H3 histone acetyltransferase activity; single-stranded DNA binding

Biological Process: positive regulation of transcription, DNA-dependent; cell aging; cytokinesis; positive regulation of mitotic cell cycle; DNA repair; oocyte maturation; regulation of cytokinesis; inner cell mass cell proliferation; negative regulation of mammary gland epithelial cell proliferation; double-strand break repair via homologous recombination; response to UV-C; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; male meiosis I; nucleotide-excision repair; double-strand break repair; response to gamma radiation; spermatogenesis; hemopoiesis; replication fork protection; brain development; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; centrosome duplication; female gonad development; response to X-ray

Disease: Pancreatic Cancer, Susceptibility To, 2; Breast-ovarian Cancer, Familial, Susceptibility To, 2; Breast Cancer; Prostate Cancer; Medulloblastoma; Glioma Susceptibility 3; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Fanconi Anemia, Complementation Group D1; Wilms Tumor 1

Chen, P-L et al. 1998. PNAS (USA)95: 5287-5292.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.